Chronic fatigue syndrome from vagus nerve infection: A psychoneuroimmunological hypothesis

Medical Hypotheses

Volumn 81, Issue 3, 2013, Pages 414-423

  VanElzakker, Michael B ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBUDILAST; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; MINOCYCLINE; MN 166; PENTOXIFYLLINE; PROPENTOFYLLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANOREXIA; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CHEMORECEPTOR; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; CYTOKINE RESPONSE; DEPRESSION; DISEASE ASSOCIATION; ELECTROSTIMULATION; FATIGUE; FEVER; FIBROMYALGIA; GLIA; GLIA CELL; HUMAN; HYPERALGESIA; ILLNESS BEHAVIOR; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFECTION; INNATE IMMUNITY; MOTOR ACTIVITY; MYALGIA; NEUROPATHIC PAIN; NONHUMAN; PHYSICAL ACTIVITY; POSITRON EMISSION TOMOGRAPHY; SENSORY NERVE; SLEEP STAGE; TRIGEMINAL NERVE; VAGOTOMY; VAGUS NERVE; VAGUS NERVE DISEASE; VAGUS NERVE INFECTION; VAGUS NERVE STIMULATION; VAGUS TONE; VIRUS INFECTION;

ANIMALIA;

CELL COMMUNICATION; CYTOKINES; FATIGUE SYNDROME, CHRONIC; HUMANS; ILLNESS BEHAVIOR; MODELS, BIOLOGICAL; VAGUS NERVE DISEASES;

EID: 84881553005     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.05.034     Document Type: Article

References (140)

1. Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group, in. Ann Intern Med 1994, 121:953-959.
2. Komaroff A.L., Fagioli L.R., Geiger A.M., et al. An examination of the working case definition of chronic fatigue syndrome. Am J Med 1996, 100(1):56-64.
3. Cairns R., Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome. Occup Med (London) 2005, 55(1):20-31.
4. Ablashi D.V., Eastman H.B., Owen C.B., et al. Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. J Clin Virol 2000, 16(3):179-191.
5. Beqaj S.H., Lerner A.M., Fitzgerald J.T. Immunoassay with cytomegalovirus early antigens from gene products p52 and CM2 (UL44 and UL57) detects active infection in patients with chronic fatigue syndrome. J Clin Pathol 2008, 61(5):623-626.
6. Kerr J.R., Tyrrell D.A.J. Cytokines in parvovirus B19 infection as an aid to understanding chronic fatigue syndrome. Curr Pain Headache Rep 2003, 7(5):333-341.
7. Komaroff A.L. Is human herpesvirus-6 a trigger for chronic fatigue syndrome?. J Clin Virol 2006, 37(Suppl. 1):S39-46.
8. Lombardi V.C., Ruscetti F.W., Das Gupta J., et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009, 326(5952):585-589.
9. Patnaik M., Komaroff A.L., Conley E., Ojo-Amaize E.A., Peter J.B. Prevalence of IgM antibodies to human herpesvirus 6 early antigen (p41/38) in patients with chronic fatigue syndrome. J Infect Dis 1995, 172(5):1364-1367.
10. Sairenji T., Yamanishi K., Tachibana Y., Bertoni G., Kurata T. Antibody responses to Epstein-Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome. Intervirology 1995, 38(5):269-273.
11. Wildman M.J., Smith E.G., Groves J., Beattie J.M., Caul E.O., Ayres J.G. Chronic fatigue following infection by Coxiellaburnetii (Q fever): Ten-year follow-up of the 1989 UK outbreak cohort. QJM 2002, 95(8):527-538.
12. Klimas N.G., Salvato F.R., Morgan R., Fletcher M.A. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990, 28(6):1403-1410.
13. Lorusso L., Mikhaylova S.V., Capelli E., Ferrari D., Ngonga G.K., Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009, 8(4):287-291.
14. Maier S.F., Watkins L.R., Fleshner M. Psychoneuroimmunology: The interface between behavior, brain, and immunity. Am Psychol 1994, 49(12):1004-1017.
15. Gacek R.R. The biology of neurotropic viruses. Adv Otorhinolaryngol 2002, 60:1-11.
16. Steiner I., Kennedy P.G.E., Pachner A.R. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol 2007, 6(11):1015-1028.
17. Yao K., Crawford J.R., Komaroff A.L., Ablashi D.V., Jacobson S. Review part 2: human herpesvirus-6 in central nervous system diseases. J Med Virol 2010, 82(10):1669-1678.
18. Lerner A.M., Beqaj S.H., Deeter R.G., Fitzgerald J.T. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. In Vivo 2007, 21(5):707-713.
19. Straus S.E., Tosato G., Armstrong G., et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 1985, 102(1):7-16.
20. Gilden D.H., Mahalingam R., Cohrs R.J., Tyler K.L. Herpesvirus infections of the nervous system. Nat Clin Pract Neurol 2007, 3(2):82-94.
21. Gleeson M., Pyne D.B., Austin J.P., et al. Epstein-Barr virus reactivation and upper-respiratory illness in elite swimmers. Med Sci Sports Exerc 2002, 34(3):411-417.
22. Gonzalez M.B., Cousins J.C., Doraiswamy P.M. Neurobiology of chronic fatigue syndrome. Prog Neuropsychopharmacol Biol Psychiatry 1996, 20(5):749-759.
23. Goehler L.E., Gaykema R.P., Hansen M.K., Anderson K., Maier S.F., Watkins L.R. Vagal immune-to-brain communication: a visceral chemosensory pathway. Auton Neurosci 2000, 85(1-3):49-59.
24. Maier S.F., Watkins L.R. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998, 105(1):83-107.
25. Dantzer R., Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007, 21(2):153-160.
26. Hansen M.K., Krueger J.M. subdiaphragmatic vagotomy blocks the sleep- and fever-promoting effects of interleukin-1beta. Am J Physiol 1997, 273(4 Pt 2):R1246-53.
27. Kapsimalis F., Basta M., Varouchakis G., Gourgoulianis K., Vgontzas A., Kryger M. Cytokines and pathological sleep. Sleep Med 2008, 9(6):603-614.
28. Majde J.A., Krueger J.M. Links between the innate immune system and sleep. J Allergy Clin Immunol 2005, 116(6):1188-1198.
29. Baumann H., Gauldie J. The acute phase response. Immunol Today 1994, 15(2):74-80.
30. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9(1):46-56.
31. Helle M., Brakenhoff J.P., De Groot E.R., Aarden L.A. Interleukin 6 is involved in interleukin 1-induced activities. Eur J Immunol 1988, 18(6):957-959.
32. Exton M.S. Infection-induced anorexia: active host defense strategy. Appetite 1997, 29(3):369-383.
33. Hermann G.E., Rogers R.C. TNF activates astrocytes and catecholaminergic neurons in the solitary nucleus: implications for autonomic control. Brain Res 2009, 1273:72-82.
34. Plata-Salamán C.R. Cytokine-induced anorexia: Behavioral. Behavioral, cellular, and molecular mechanisms. Ann N Y Acad Sci 1998, 856:160-170.
35. Watkins L.R., Maier S.F. The pain of being sick: Implications of immune-to-brain communication for understanding pain. Annu Rev Psychol 2000, 51:29-57.
36. Maier S.F., Wiertelak E.P., Martin D., Watkins L.R. Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin. Brain Res 1993, 623(2):321-324.
37. Meeus M., Nijs J., Huybrechts S., Truijen S. Evidence for generalized hyperalgesia in chronic fatigue syndrome: A case control study. Clin Rheumatol 2010, 29(4):393-398.
38. Vecchiet L., Montanari G., Pizzigallo E., et al. Sensory characterization of somatic parietal tissues in humans with chronic fatigue syndrome. Neurosci Lett 1996, 208(2):117-120.
39. Barrientos R.M., Higgins E.A., Biedenkapp J.C., Sprunger D.B., et al. Peripheral infection and aging interact to impair hippocampal memory consolidation. Neurobiol Aging 2006, 27(5):723-732.
40. Sparkman N.L., Buchanan J.B., Heyen J.R.R., Chen J., Beverly J.L., Johnson R.W. Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci 2006, 26(42):10709-10716.
41. Goshen I., Yirmiya R. The role of proinflammatory cytokines in memory processes and neural plasticity. Psychoneuroimmunology 2007, 337-377. Elsevier Inc., Amsterdam. 4th ed. R. Ader (Ed.).
42. Kelley K.W., Bluthé R.M., Dantzer R., et al. Cytokine-induced sickness behavior. Brain Behav Immun 2003, 17(Suppl. 1):S112-8.
43. Licinio J., Kling M.A., Hauser P. Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol 1998, 25(Suppl. 1):30-38.
44. Reichenberg A., Yirmiya R., Schuld A., et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001, 58(5):445-452.
45. Wilson C.J., Finch C.E., Cohen H.J. Cytokines and cognition-the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 2002, 50(12):2041-2056.
46. Miller D.B., O'Callaghan J.P. Depression, cytokines, and glial function. Metab Clin Exp 2005, 54(Suppl. 1):33-38.
47. Heinrich P.C., Castell J.V., Andus T. Interleukin-6 and the acute phase response. Biochem J 1990, 265(3):621-636.
48. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982, 389:39-48.
49. Maes M., Mihaylova I., De Ruyter M. Lower serum zinc in chronic fatigue syndrome (CFS): relationships to immune dysfunctions and relevance for the oxidative stress status in CFS. J Affect Disord 2006, 90(2-3):141-147.
50. Kubota K. Kuniomi Ishimori and the first discovery of sleep-inducing substances in the brain. Neurosci Res 1989, 6(6):497-518.
51. Kapsimalis F., Richardson G., Opp M.R., Kryger M. Cytokines and normal sleep. Curr Opin Pulm Med 2005, 11(6):481-484.
52. Turrin N.P., Plata-Salamán C.R. Cytokine-cytokine interactions and the brain. Brain Res Bull 2000, 51(1):3-9.
53. Watkins L.R., Maier S.F., Goehler L.E. Cytokine-to-brain communication: a review & analysis of alternative mechanisms. Life Sci 1995, 57(11):1011-1026.
54. Broderick G., Fuite J., Kreitz A., Vernon S.D., Klimas N., Fletcher M.A. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun 2010, 24(7):1209-1217.
55. Cannon J.G., Angel J.B., Ball R.W., Abad L.W., Fagioli L., Komaroff A.L. Acute phase responses and cytokine secretion in chronic fatigue syndrome. J Clin Immunol 1999, 19(6):414-421.
56. Fletcher M.A., Zeng X.R., Barnes Z., Levis S., Klimas N.G. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009, 7:96.
57. Patarca R. Cytokines and chronic fatigue syndrome. Ann N Y Acad Sci 2001, 933:185-200.
58. Hart B.L. Behavior of sick animals. Vet Clin North Am Food Anim Pract 1987, 3(2):383-391.
59. Johnson R.W. The concept of sickness behavior: a brief chronological account of four key discoveries. Vet Immunol Immunopathol 2002, 87(3-4):443-450.
60. Maier S.F., Goehler L.E., Fleshner M., Watkins L.R. The role of the vagus nerve in cytokine-to-brain communication. Ann N Y Acad Sci 1998, 840:289-300.
61. Barnden L.R., Crouch B., Kwiatek R., et al. A brain MRI study of chronic fatigue syndrome: evidence of brainstem dysfunction and altered homeostasis. NMR Biomed 2011, 24(10):1302-1312.
62. De Becker P., Dendale P., De Meirleir K., Campine I., Vandenborne K., Hagers Y. Autonomic testing in patients with chronic fatigue syndrome. Am J Med 1998, 105(3A):22S-26S.
63. Stewart J., Weldon A., Arlievsky N., Li K., Munoz J. Neurally mediated hypotension and autonomic dysfunction measured by heart rate variability during head-up tilt testing in children with chronic fatigue syndrome. Clin Auton Res 1998, 8(4):221-230.
64. Stewart J.M. Autonomic nervous system dysfunction in adolescents with postural orthostatic tachycardia syndrome and chronic fatigue syndrome is characterized by attenuated vagal baroreflex and potentiated sympathetic vasomotion. Pediatr Res 2000, 48(2):218-226.
65. Wyller V.B., Saul J.P., Amlie J.P., Thaulow E. Sympathetic predominance of cardiovascular regulation during mild orthostatic stress in adolescents with chronic fatigue. Clin Physiol Funct Imaging 2007, 27(4):231-238.
66. Wyller V.B., Barbieri R., Thaulow E., Saul J.P. Enhanced vagal withdrawal during mild orthostatic stress in adolescents with chronic fatigue. Ann Noninvasive Electrocardiol 2008, 13(1):67-73.
67. Cordero D.L., Sisto S.A., Tapp W.N., LaManca J.J., Pareja J.G., Natelson B.H. Decreased vagal power during treadmill walking in patients with chronic fatigue syndrome. Clin Auton Res 1996, 6(6):329-333.
68. Powley T.L., Phillips R.J. Musings on the wanderer: what's new in our understanding of vago-vagal reflexes? I. Morphology and topography of vagal afferents innervating the GI tract. Am J Physiol Gastrointest Liver Physiol 2002, 283(6):G1217.
69. Berthoud H.R., Neuhuber W.L. Functional and chemical anatomy of the afferent vagal system. Auton Neurosci 2000, 85(1-3):1-17.
70. Grundy D., Al-Chaer E.D., Aziz Q., et al. Fundamentals of neurogastroenterology: basic science. Gastroenterology 2006, 130(5):1391-1411.
71. Powley T.L., Spaulding R.A., Haglof S.A. Vagal afferent innervation of the proximal gastrointestinal tract mucosa: chemoreceptor and mechanoreceptor architecture. J Comp Neurol 2011, 519(4):644-660.
72. Powley T.L., Prechtl J.C., Fox E.A., Berthoud H.R. Anatomical considerations for surgery of the rat abdominal vagus: distribution, paraganglia and regeneration. J Auton Nerv Syst 1983, 9(1):79-97.
73. Wang F.-B., Powley T.L. Vagal innervation of intestines: afferent pathways mapped with new en bloc horseradish peroxidase adaptation. Cell Tissue Res 2007, 329(2):221-230.
74. Hanani M. Satellite glial cells in sympathetic and parasympathetic ganglia: in search of function. Brain Res Rev 2010, 64(2):304-327.
75. Goehler L.E., Relton J.K., Dripps D., et al. Vagal paraganglia bind biotinylated interleukin-1 receptor antagonist: a possible mechanism for immune-to-brain communication. Brain Res Bull 1997, 43(3):357-364.
76. Kummer W., Neuhuber W.L. Vagal paraganglia of the rat. J Electron Microsc Tech 1989, 12(4):343-355.
77. Felten S.Y., Felten D.L. Innervation of the lymphoid tissue. Psychoneuroimmunology 1991, 27-67. Academic Press Inc., New York. 2nd ed. R. Ader, N. Cohen, D.L. Felten (Eds.).
78. Haydon P.G. Glia: listening and talking to the synapse. Nat Rev Neurosci 2001, 2(3):185-193.
79. Smith K. Neuroscience: settling the great glia debate. Nature 2010, 468(7321):160-162.
80. Watkins L.R., Milligan E.D., Maier S.F. Glial activation: a driving force for pathological pain. Trends Neurosci 2001, 24(8):450-455.
81. Adachi A. Projection of the hepatic vagal nerve in the medulla oblongata. J Auton Nerv Syst 1984, 10(3-4):287-293.
82. Ek M., Kurosawa M., Lundeberg T., Ericsson A. Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins. J Neurosci 1998, 18(22):9471-9479.
83. Niijima A. The afferent discharges from sensors for interleukin 1 beta in the hepatoportal system in the anesthetized rat. J Auton Nerv Syst 1996, 61(3):287-291.
84. Goehler L.E., Gaykema R.P., Hammack S.E., Maier S.F., Watkins L.R. Interleukin-1 induces c-fosimmunoreactivity in primary afferent neurons of the vagus nerve. Brain Res 1998, 804(2):306-310.
85. Konsman J.P., Luheshi G.N., Bluthé R.M., Dantzer R. The vagus nerve mediates behavioural depression, but not fever, in response to peripheral immune signals; a functional anatomical analysis. Eur J Neurosci 2000, 12(12):4434-4446.
86. Luheshi G.N., Bluthé R.M., Rushforth D., et al. Vagotomy attenuates the behavioural but not the pyrogenic effects of interleukin-1 in rats. Auton Neurosci 2000, 85(1-3):127-132.
87. Kapás L., Hansen M.K., Chang H.Y., Krueger J.M. Vagotomy attenuates but does not prevent the somnogenic and febrile effects of lipopolysaccharide in rats. Am J Physiol 1998, 274(2 Pt 2):R406-11.
88. Fleshner M., Goehler L.E., Schwartz B.A., et al. Thermogenic and corticosterone responses to intravenous cytokines (IL-1beta and TNF-alpha) are attenuated by subdiaphragmatic vagotomy. J Neuroimmunol 1998, 86(2):134-141.
89. Romanovsky A.A., Simons C.T., Székely M., Kulchitsky V.A. The vagus nerve in the thermoregulatory response to systemic inflammation. Am J Physiol 1997, 273(1 Pt 2):R407-13.
90. Watkins L.R., Goehler L.E., Relton J.K., et al. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication. Neurosci Lett 1995, 183(1-2):27-31.
91. Sehic E., Blatteis C.M. Blockade of lipopolysaccharide-induced fever by subdiaphragmatic vagotomy in guinea pigs. Brain Res 1996, 726(1-2):160-166.
92. Milligan E.D., Watkins L.R. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009, 10(1):23-36.
93. Wieseler-Frank J., Maier S.F., Watkins L.R. Glial activation and pathological pain. Neurochem Int 2004, 45(2-3):389-395.
94. Watkins L.R., Hansen M.K., Nguyen K.T., Lee J.E., Maier S.F. Dynamic regulation of the proinflammatory cytokine, interleukin-1beta: molecular biology for non-molecular biologists. Life Sci 1999, 65(5):449-481.
95. Milligan E.D., O'Connor K.A., Nguyen K.T., et al. Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines. J Neurosci 2001, 21(8):2808-2819.
96. Milligan E.D., Mehmert K.K., Hinde J.L., et al. Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120. Brain Res 2000, 861(1):105-116.
97. Conn C.A., McClellan J.L., Maassab H.F., Smitka C.W., Majde J.A., Kluger M.J. Cytokines and the acute phase response to influenza virus in mice. Am J Physiol 1995, 268(1 Pt 2):R78-84.
98. Natelson B.H., Haghighi M.H., Ponzio N.M. Evidence for the presence of immune dysfunction in chronic fatigue syndrome. Clin Diagn Lab Immunol 2002, 9(4):747-752.
99. Togo F., Natelson B.H., Adler G.K., et al. Plasma cytokine fluctuations over time in healthy controls and patients with fibromyalgia. Exp Biol Med 2009, 234(2):232-240.
100. Petrovsky N. Whole blood assays and the influence of circadian rhythmicity on human cytokine measurement. Interleukin Protocols. Methods in Molecular Medicine 2001, Totowa, NJ, Humana Press. L.A.J. O'Neill, A. Bowie (Eds.).
101. Kogelnik A.M., Loomis K., Hoegh-Petersen M., Rosso F., Hischier C., Montoya J.G. Use of valganciclovir in patients with elevated antibody titers against human Herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol 2006, 37(Suppl. 1):33-38.
102. Chambers D., Bagnall A.-M., Hempel S., Forbes C. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review. J R Soc Med 2006, 99(10):506-520.
103. Devanur L.D., Kerr J.R. Chronic fatigue syndrome. J Clin Virol 2006, 37(3):139-150.
104. Evengård B., Jonzon E., Sandberg A., Theorell T., Lindh G. Differences between patients with chronic fatigue syndrome and with chronic fatigue at an infectious disease clinic in Stockholm, Sweden. Psychiatry Clin Neurosci 2003, 57(4):361-368.
105. Jason L.A., Plioplys A.V., Torres-Harding S., Corradi K. Comparing symptoms of chronic fatigue syndrome in a community-based versus tertiary care sample. J Health Psychol 2003, 8(4):459-464.
106. Reyes M., Nisenbaum R., Hoaglin D.C. Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. Arch Intern Med 2003, 163(13):1530-1536.
107. Khasar S.G., Isenberg W.M., Miao F.J., Gear R.W., Green P.G., Levine J.D. Gender and gonadal hormone effects on vagal modulation of tonic nociception. YJPAI 2001, 2(2):91-100.
108. Khasar S.G., Green P.G., Gear R.W., Isenberg W., Levine J.D. Gonadal hormones do not account for sexual dimorphism in vagal modulation of nociception in the rat. YJPAI 2003, 4(4):190-196.
109. Li B.-Y., Qiao G.-F., Feng B., Zhao R.-B., Lu Y.-J., Schild J.H. Electrophysiological and neuroanatomical evidence of sexual dimorphism in aortic baroreceptor and vagal afferents in rat. Am J Physiol Regul Integr Comp Physiol 2008, 295(4):R1301-10.
110. Oh E.J., Thompson L.P., Weinreich D. Sexually dimorphic regulation of NK-1 receptor-mediated electrophysiological responses in vagal primary afferent neurons. J Neurophysiol 2000, 84(1):51-56.
111. Lahita R.G. The basis for gender effects in the connective tissue diseases. Ann Med Interne 1996, 147(4):241-247.
112. Levine J.D., Khasar S.G., Green P.G. Neurogenic inflammation and arthritis. Ann N Y Acad Sci 2006, 1069:155-167.
113. Blessing W.W., Li Y.W., Wesselingh S.L. Transneuronal transport of herpes simplex virus from the cervical vagus to brain neurons with axonal inputs to central vagal sensory nuclei in the rat. Neuroscience 1991, 42(1):261-274.
114. Fischer C.P. Interleukin-6 in acute exercise and training: what is the biological relevance?. Exerc Immunol Rev 2006, 12:6-33.
115. White A.T., Light A.R., Hughen R.W., et al. Severity of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue syndrome. Psychophysiology 2010, 47(4):615-624.
116. Tang S.C., Jeng J.S., Liu H.M., Yip P.K. Isolated vagus nerve palsy probably associated with herpes simplex virus infection. Acta Neurol Scand 2001, 104(3):174-177.
117. El Tahry R., Raedt R., Mollet L., et al. A novel implantable vagus nerve stimulation system (ADNS-300) for combined stimulation and recording of the vagus nerve: pilot trial at Ghent University Hospital. Epilepsy Res 2010, 92(2-3):231-239.
118. Politis M., Su P., Piccini P. Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol 2012, 3:96.
119. Hutchinson M.R., Shavit Y., Grace P.M., Rice K.C., Maier S.F., Watkins L.R. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev 2011, 63(3):772-810.
120. Cho Y., Crichlow G.V., Vermeire J.J., et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA 2010, 107(25):11313-11318.
121. Alexander J.K., Cox G.M., Tian J.-B., et al. Macrophage migration inhibitory factor (MIF) is essential for inflammatory and neuropathic pain and enhances pain in response to stress. Exp Neurol 2012, 236(2):351-362.
122. Suzumura A., Ito A., Yoshikawa M., Sawada M. Ibudilast suppresses TNF-alpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res 1999, 837(1-2):203-212.
123. Chao C.C., Hu S. Tumor necrosis factor-alpha potentiates glutamate neurotoxicity in human fetal brain cell cultures. Dev Neurosci 1994, 16(3-4):172-179.
124. Aicher S.A., Sharma S., Pickel V.M. N-methyl-d-aspartate receptors are present in vagal afferents and their dendritic targets in the nucleus tractus solitarius. Neuroscience 1999, 91(1):119-132.
125. Kiebala M., Maggirwar S.B. Ibudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency virus-1 Tat-mediated activation of microglial cells. PLOS ONE 2011, 6(4):e18633.
126. Kawasaki A., Hoshino K., Osaki R., Mizushima Y., Yano S. Effect of ibudilast, a novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma. J Asthma 1992, 29(4):245-252.
127. Hudnall S.D., Chen T., Allison P., Tyring S.K., Heath A. Herpesvirus prevalence and viral load in healthy blood donors by quantitative real-time polymerase chain reaction. Transfusion 2008, 48(6):1180-1187.
128. Rush A.J., Siefert S.E. Clinical issues in considering vagus nerve stimulation for treatment-resistant depression. Exp Neurol 2009, 219(1):36-43.
129. Mauskop A. Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia 2005, 25(2):82-86.
130. Borovikova L.V., Ivanova S., Zhang M., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405(6785):458-462.
131. Kirchner A., Birklein F., Stefan H., Handwerker H.O. Left vagus nerve stimulation suppresses experimentally induced pain. Neurology 2000, 55(8):1167-1171.
132. Randich A., Gebhart G.F. Vagal afferent modulation of nociception. Brain Res Brain Res Rev 1992, 17(2):77-99.
133. Watkins L.R., Goehler L.E., Relton J., Brewer M.T., Maier S.F. Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. Brain Res 1995, 692(1-2):244-250.
134. Ellrich J. Transcutaneous vagus nerve stimulation. Eur Neurol Rev 2011, 6:262-264.
135. Tanaka M., Watanabe Y. A new hypothesis of chronic fatigue syndrome: co-conditioning theory. Med Hypotheses 2010, 75(2):244-249.
136. Madine G. A New perspective on the treatment of myalgic encephalomyelitis/chronic fatigue syndrome. Euro J Clin Hypnosis 2008, 8(1):2-8.
137. White P.D., Goldsmith K.A., Johnson A.L., et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): A randomised trial. Lancet 2011, 377(9768):823-836.
138. Fekete E.M., Antoni M.H., Schneiderman N. Psychosocial and behavioral interventions for chronic medical conditions. Curr Opin Psychiatr 2007, 20(2):152-157.
139. Shapiro J.S. Does varicella-zoster virus infection of the peripheral ganglia cause chronic fatigue syndrome?. Med Hypotheses 2009, 73(5):728-734.
140. Maes M. An intriguing and hitherto unexplained co-occurrence: depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):784-794.